Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yamini Menon

Rheumatology Cordova, TN Medical Doctor

NPI 1386696680 CMS profile 334647

540 Trinity Creek Cv, Cordova, TN 38018

Open in the dashboard

General payments

$1,298

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yamini Menon of Cordova, TN is reported in the CMS Open Payments database as having received $1,298 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $639 33
2024 General $300 14
2023 General $107 6
2022 General $79 4
2021 General $119 8
2020 General $24 2
2019 General $28 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yamini Menon
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Yamini Menon were reported at $639. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Yamini Menon Rheumatology median Middle half National median
2019 $28 $744 $153–$2,687 $163
2020 $24 $462 $98–$2,027 $114
2021 $119 $531 $101–$2,153 $132
2022 $79 $627 $125–$2,303 $149
2023 $107 $741 $145–$2,524 $160
2024 $300 $830 $166–$2,660 $164
2025 $639 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $532 29 payments
  2. AbbVie, Inc. $293 14 payments
  3. E.R. Squibb & Sons, L.L.C. $166 7 payments
  4. Horizon Therapeutics plc $102 8 payments
  5. Pfizer Inc. $83 5 payments
  6. Sandoz Inc. $41 2 payments
  7. Genzyme Corporation $29 1 payment
  8. Novartis Pharmaceuticals Corporation $24 1 payment
  9. Alexion Pharmaceuticals, Inc. $18 1 payment
  10. Genentech USA, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,298 69 payments
Products named General payments · program years 2019–2025
  1. Otezla $276 15 payments
  2. RINVOQ $265 13 payments
  3. Enbrel $209 11 payments
  4. ORENCIA $166 7 payments
  5. TAVNEOS $130 9 payments
  6. KRYSTEXXA Inflammation/Rare Disease $126 5 payments
  7. KRYSTEXXA Krystexxa $102 8 payments
  8. XELJANZ $64 4 payments
  9. COMIRNATY $30 2 payments
  10. KEVZARA $29 1 payment
  11. Other $189 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,240

Median for Rheumatology: 1,511

Drug cost

$818,059

Median for Rheumatology: $1,139,948

Branded share of claims

38.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 44 $359,238
Enbrel Sureclick Etanercept Brand 29 $210,982
Humira Pen Adalimumab Brand 19 $159,826
Actemra Tocilizumab Brand 13 $58,362
Hydroxychloroquine Sulfate Generic 184 $7,010
Methotrexate Methotrexate Sodium Brand 221 $6,525
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 121 $3,862
Azathioprine Generic 21 $2,634
Leflunomide Generic 50 $2,214
Prednisone Generic 210 $1,458

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$780,254

Of which drugs: $698,766

Medicare patients

337

Average age 71

Services billed

87,535

290 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 31%
Diabetes 26%
Ischemic heart disease 26%
Depression 23%
Chronic kidney disease 20%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tocilizumab, 1 mg J3262 Office 15 59,080 $265,381
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 15 4,925 $166,059
Injection, golimumab, 1 mg, for intravenous use J1602 Office 29 13,250 $120,294
Injection, denosumab, 1 mg J0897 Office 23 1,680 $33,530
Vaccine for influenza for injection into muscle 90653 Office 15 15 $1,227
Infusion, normal saline solution, 250 cc J7050 Office 68 295 $152

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $106
$106 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $69
$69 — 4,925
TAVNEOS
  • Amgen Inc. $34
$34 — —
Otezla
  • Amgen Inc. $27
$27 — —
Enbrel
  • Amgen Inc. $27
$27 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record